tbuckley/cabot-search huggingface dataset:
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
Authors: M. Pegram, J. Forbes, T. Pienkowski, V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, J. Crown, H. Taupin, D. Slamon
Journal: Journal of Clinical Oncology (2007)

LBA1008 Background: Based on preclinical synergism between docetaxel (T), carboplatin (C) and trastuzumab (H), BCIRG conducted a phase III trial in HER2-positive MBC to evaluate efficacy and safety of H in combination with T or TC. Methods: 263 patients (pts) with HER2 FISH+ MBC were randomized to TH (H with T 100mg/m 2 ) or TCH (H with T 75mg/m 2 and C AUC=6). Chemotherapy was given every 3 weeks (q3w) for 8 cycles with weekly H at 2mg/kg (loading dose of 4 mg/kg) followed by H q3w at 6 mg/kg until progression. Pts were stratified by centre and prior (neo) adjuvant taxane chemotherapy. Primary endpoint was Time To disease Progression (TTP). Secondary endpoints include overall survival, response rate, duration of response (DR), clinical benefit (CB) and safety. Results: 131 pts were treated in each arm Pt characteristics were well balanced in both groups. A first efficacy analysis was conducted at 204 events. There was no significant difference between TH and TCH in median TTP (11.1 vs 10.4 mos, p=0.57), ORR (73% in both arms), DR (10.7 vs 9.4 mos) and CB (67% in both arms). At 39 months of median follow-up, median overall survival was 36.40 and 36.57 months in TH and TCH arms respectively. More patients on TCH received the max number of chemotherapy cycles, and numerically fewer patients on TCH discontinued treatment as a result of non hematological toxicity. The most common gr 3/4 toxicities were: Neutropenic infection that was 16.8% vs 9.2% respectively for TH and TCH, thrombocytopenia (2% vs 15%), asthenia (5% vs 12%), anemia (5% vs 11%), and diarrhea (2% vs 10%). Two pts died (1.5%) due to sepsis in TCH. Absolute LVEF decline &gt; 15 % were seen in 5.5 % vs 6.7 % of pts. One pt (0.8%) had a symptomatic CHF in TH arm. Conclusion: Both TH (T 100) and TCH (T 75) were highly effective treatment regimens in women having HER2-positive MBC, demonstrating high response rates, median TTP &gt; 10 months, and median overall survival &gt; 36 months in both TH and TCH. Cardiac toxicity was no significant problem with either treatment. [Table: see text]
Differential Response to Cytochalasin B Among Cells Transformed by DNA and RNA Tumor Viruses 2
Authors: Frank J. O’Neill, Thomas H. Miller, Jean Hoen, Barbara Stradley, Vincent Devlahovich
Journal: JNCI Journal of the National Cancer Institute (1975)

Mouse, hamster, rat, human, and chick cells were transformed by RNA and DNA tumor viruses: simian virus 40, adenovirus type 7, Kirsten mouse sarcoma virus (Ki-MuSV), Moloney mouse sarcoma virus, and Rous sarcoma virus. All cultures of transformed cells grew to high concentration densities. Normal and transformed cells were treated with cytochalasin B (CB) at concentrations preventing cytoplasmic cleavage. Cells altered by DNA tumor viruses responded to CB with numerous nuclear divisions resulting in highly multinucleated cells. All but one line of cells transformed by RNA tumor viruses responded to CB with usually only one and occasionally two nuclear divisions. Only birrucleated cells were formed. One clone of CB-treated BALB/c mouse embryo fibroblasts transformed by Ki-MuSV showed numerous cells with four and five nuclei. However, in contrast to cells transformed by DNA viruses, few cells had seven or more nuclei. These results suggest that, in the presence of CB, cells transformed by DNA tumor viruses show uncontrolled nuclear division, whereas cells transformed by RNA tumor viruses show controlled nuclear dlvision.
Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient
Authors: Matthew J. Budoff, Paolo Raggi, George A. Beller, Daniel S. Berman, Regina S. Druz, Shaista Malik, Vera H. Rigolin, Wm. Guy Weigold, Prem Soman
Journal: JACC. Cardiovascular imaging (2016)
When the BRCA test is negative—Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA+)
Authors: S. Verma, S. F. Dent, L. Paquet, L. Bitonti
Journal: Journal of Clinical Oncology (2008)

1534 Background: Much attention has been focused on screening and risk reduction, including prophylactic mastectomy (PM) or oophorectomy (PO) in BRCA+ mutation carriers (Rebbeck 1999, Eisen 2005, Kauff 2007). In families with a known BRCA mutation (BRCA+) or a history of hereditary breast cancer (BC) or ovarian cancer (OC), relatives in whom a mutation is not identified are considered ‘high risk’ and prevention strategies, including the need for PM or PO are undefined. We undertook a prospective evaluation of relatives from families wherein a BRCA mutation was present, with the intent to understand how BRCA- members view and manage their risks of BC or OC over time. Methods: Participants were 1st and 2nd degree unaffected relatives of 27 BRCA+ patients known to have BC or OC (20 BRCA1 and 7 BRCA2), referred to the high risk clinic for screening and prevention advice. Prior to and following genetic testing, participants were evaluated for individual risk factors for BC, self-perceived risk of BC, anxiety, prevention preferences and intentions. Genetic testing identified 62 BRCA+ (med. age 44) and 53 BRCA- (med. age 39) relatives, median Gail scores were 3.10 and 2.59 respectively. Results: Prior to genetic testing, 90% of all patients, regardless of BRCA status reported ‘extreme’ anxiety and a ‘very high’ perceived lifetime risk of BC. Two-thirds expressed interest in PM and/or PO. After genetic testing, 50% and 90% in the BRCA+ cohort, and 20% and 32% in the BRCA- cohort underwent PM and PO respectively. Less than 10% chose chemoprevention (CP) in both groups. At 6 months post PM or PO 80% and 65% of BRCA+ and BRCA- cohorts expressed decisional satisfaction. Significant factors determining PM in the BRCA- cohort were: age (>40), 1st degree relative with BC, family history of BRCA1 mutation, ‘high’ anxiety persisting >1 year. Conclusions: BRCA- relatives of BRCA+ families believe that they are highly susceptible to BC, experiencing high anxiety post-test disclosure and have an unexpectedly high rate of PM and PO. CP is unexpectedly low in both cohorts. Improved strategies for assessment and management of risk in these patients are required. No significant financial relationships to disclose.
The effect of smoking on the treatment outcome in patients with pulmonary tuberculosis: A prospective cohort study
Authors: Myla Castillo, Ma. Encarnita Limpin
Journal: European Respiratory Journal (2011)

Smoking and tuberculosis have great impact on health. Smoking is prevalent worldwide occurring in 20% of adults while uberculosis is a universal problem. Studies have shown that although smoking has no etiological role in TB, higher prevalence of TB has been observed in smokers. However, only few studies have evaluated the impact of smoking on TB treatment.  General Objective: To determine the effect of smoking on the treatment outcome among patients being treated for pulmonary tuberculosis.  Specific Objectives: To determine the prevalence of smoking among patients with PTB, incidence of treatment success and failure among patients being treated for PTB and to determine the association between smoking and treatment outcomes.   Methodology:  A prospective cohort study done in Dr. Jose Rodriguez Memorial Hospital, Directly Observe Treatment Strategy (DOTS) Center included all patients diagnosed with pulmonary tuberculosis, ages 18 years and above under the DOTS program. Demographics, co morbidities and smoking history were obtained by standardized interview. Initially CXR and sputum AFB were done. Sputum examination was repeated on 2nd, 4th month and on completion of treatment.   Result:  Of the 83 patients enrolled, 29 were non smoker while 54 had smoking history (24-previous smoker, 30- current smoker). Cavitary PTB was common among patients with smoking history. Only 3 patients had treatment failure, one was previous smoker while the other 2 were current smoker.   Conclusion:  Patients under DOTS program have high success rate. Although the study did not reach statistical significance, there was a strong trend on the association of smoking with treatment failure.
Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used
Authors: Kelly M. McMasters, Todd M. Tuttle, David J. Carlson, C. Matthew Brown, R. Dirk Noyes, Rebecca L. Glaser, Donald J. Vennekotter, Peter S. Turk, Peter S. Tate, Armando Sardi, Patricia B. Cerrito, Michael J. Edwards
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Previous studies have demonstrated the feasibility of sentinel lymph node (SLN) biopsy for nodal staging of patients with breast cancer. However, unacceptably high false-negative rates have been reported in several studies, raising doubt about the applicability of this technique in widespread surgical practice. Controversy persists regarding the optimal technique for correctly identifying the SLN. Some investigators advocate SLN biopsy using injection of a vital blue dye, others recommend radioactive colloid, and still others recommend the use of both agents together. PATIENTS AND METHODS: A total of 806 patients were enrolled by 99 surgeons. SLN biopsy was performed by single-agent (blue dye alone or radioactive colloid alone) or dual-agent injection at the discretion of the operating surgeon. All patients underwent attempted SLN biopsy followed by completion level I/II axillary lymph node dissection to determine the false-negative rate. RESULTS: There was no significant difference (86% v 90%) in the SLN identification rate among patients who underwent single- versus dual-agent injection. The false-negative rates were 11.8% and 5.8% for single- versus dual-agent injection, respectively (P &lt; .05). Dual-agent injection resulted in a greater mean number of SLNs identified per patient (2.1 v 1.5; P &lt; .0001). The SLN identification rate was significantly less for patients older than 50 years as compared with that of younger patients (87.6% v 92.6%; P = .03). Upper-outer quadrant tumor location was associated with an increased likelihood of a false-negative result compared with all other locations (11.2% v 3.9%; P &lt; .05). CONCLUSION: In multi-institutional practice, SLN biopsy using dual-agent injection provides optimal sensitivity for detection of nodal metastases. The acceptable SLN identification and false-negative rates associated with the dual-agent injection technique indicate that this procedure is a suitable alternative to routine axillary dissection across a wide spectrum of surgical practice and hospital environments.
A standardized grading scale for reconstructive process surgery in head and neck cancer.
Authors: G. Poissonnet, O. Dassonville, A. Bozec, F. Peyrade, P. Mahdyoun, F. Demard, J. Santini
Journal: Journal of Clinical Oncology (2010)

e16000 Background: Following carcinologic operative step, head and neck cancer surgery requires a reconstructive step involving local or regional, pedicled or free flaps. Although the reconstructive technique specifics depend mainly on the surgical team, the functional goal is so important that the best choice should be fully understood and discussed by the multidisciplinary team, including all involved medical staff. At the present time, the too numerous reconstructive procedures explain the great difficulty in including surgical reconstructive treatments in head and neck cancer prospective international studies, particularly in functional and quality of life evaluation. Methods: We have retrospectively established this scale in head and neck reconstructive surgery, based on 197 pedicled flaps and 225 free flaps performed from 2004 to 2008. Results: Therefore, we are proposing the Poissonville 2009 grading scale (Table), gathering the various head and neck reconstructive procedures according to the surgical difficulty and duration. It can be easily applied to any head and neck anatomical area. Conclusions: This scale is aiming at including the reconstructive step within the existing therapeutic guidelines, allowing the inclusion of the patient's medical condition and functional requirements in the therapeutic choice. Moreover, the cost effectiveness of the surgery could be evaluated by this scale according to the surgical procedure as others cancer staging classifications. Standardized grading scale of flaps for head and neck reconstructive surgery (Poissonville 2009) S type Without flap Direct suture, healing, skin graft M type Local pedicled flaps FAMM, myocutaneous buccinator, nasolabial L type Regional head and neck pedicled flaps Platysma, infrahyoid myocutaneous, temporoparietal fascia XL type Beyond head and neck area pedicled flaps Myocutaneous pectoralis major, myocutaneous latissimus dorsi XXL type Free flaps with microvascular surgery NB(no bone) Fasciocutaneous or myocutaneous flaps Radial forearm, anterolateral thigh, lateral arm, scapular, latissimus dorsi B(bone) Osteocutaneous flaps Fibular, scapular, iliac crest D Digestive flaps Digestive Jejunal, gastro-omental No significant financial relationships to disclose.
Tissue microarrays (TMAS) in colorectal cancer: Study of clinical and molecular markers
Authors: R. Serrano, M. Gómez, X. Farre, M. Méndez, J. De La Haba, R. Morales, L. Sanchez, I. Barneto, E. Aranda
Journal: Journal of Clinical Oncology (2004)

9665 Background: TMAS are a powerful tool for testing a large number of molecular parameters in hundreds of tissue samples. This technique can help us to improve our knowledge of molecular markers used to predict disease evolution.To study clinical factors and the expression pattern of proteins including Rb, p53, ki67, p21, p16, p27, cyclins (A, B1, D1, D3 y E), cyclin dependent kinases (cdks) 1, 2 and 6, Survivin, bcl-2 and activated caspase 3 in 71 patients diagnosed of carcinoma colorectal, of which 31 had metastasic disease at diagnosis 22 relapsed and 18 were of free disease. Patients were included in multicentric clinical trials and had received chemotherapy. Methods: Two TMAS were constructed by acquiring 1 mm cylindrical biopsies from each of formalin-fixed paraffin-embedded tumors and controls and spaced 1.5 mm. As dependent variables we analysed overall survival (OS) and survival after relapsed (SV2). As independent variables we studied age, gender, tumor localization, TNM, lymph node involvement, differentiation grade, liver metastases, symptoms at metastatic disease, and single or multiple metastatic localizations. The univariate analysis was carried out for each one of the variables by means of the Kaplan-Meier method and the multivariate analysis was performed using the Cox regression model. Results: According to the univariate analysis the statistically significant variables were differentiation grade, liver metastasis, symptoms, number localization, cdk1,cdk 2,cdk6, cyclin A, D3, ki-67, p53 and survivin for OS, and differentiation grade, symtoms, number localization, activated caspase 3, cdk2, cdk6, cyclin D3, ki67, p21 and survivin for SV2. In the multivariate analysis those variables that reached a significant value p≤ 0.2 were included. Conclusions: In this study clinical factors such as differentiation grade, symptoms, number localization were independent prognostic factors for OS and symptoms for SV2; none of proteins analysed correlated with OS or SV2 in multivariate analysis. No significant financial relationships to disclose.
Biological Mesh Implants for Abdominal Hernia Repair
Authors: Sergio Huerta, Anubodh Varshney, Prachi M. Patel, Helen G. Mayo, Edward H. Livingston
Journal: JAMA Surgery (2016)

Expensive biological mesh materials are increasingly used to reinforce abdominal wall hernia repairs. The clinical and cost benefit of these materials are unknown.To review the published evidence on the use of biological mesh materials and to examine the US Food and Drug Administration (FDA) approval history for these devices.Search of multiple electronic databases (Ovid, MEDLINE, EMBASE, Cochrane Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, and Cochrane National Health Service Economic Evaluation Database) to identify articles published between 1948 and June 30, 2015, on the use of biological mesh materials used to reinforce abdominal wall hernia repair. Keywords searched included surgical mesh, abdominal hernia, recurrence, infection, fistula, bioprosthesis, biocompatible materials, absorbable implants, dermis, and collagen. The FDA online database for 510(k) clearances was reviewed for all commercially available biological mesh materials. The median national price for mesh materials was established by a benchmarking query through several Integrated Delivery Network and Group Purchasing Organization tools.Of 274 screened articles, 20 met the search criteria. Most were case series that reported results of convenience samples of patients at single institutions with a variety of clinical problems. Only 3 of the 20 were comparative studies. There were no randomized clinical trials. In total, outcomes for 1033 patients were described. Studies varied widely in follow-up time, operative technique, meshes used, and patient selection criteria. Reported outcomes and clinical outcomes, such as fistula formation and infection, were inconsistently reported across studies. Conflicts of interest were not reported in 16 of the 20 studies. Recurrence rates ranged from 0% to 80%. All biological mesh devices were approved by the FDA based on substantial equivalence to a group of nonbiological predicate devices that, on average, were one-third less costly.There is insufficient evidence to determine the extra costs associated with or the clinical efficacy of biological mesh materials for the repair of abdominal wall hernia.
Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation
Authors: Jozine M. ter Maaten, Kevin Damman, Marianne C. Verhaar, Walter J. Paulus, Dirk J. Duncker, Caroline Cheng, Loek van Heerebeek, Hans L. Hillege, Carolyn S.P. Lam, Gerjan Navis, Adriaan A. Voors
Journal: European Journal of Heart Failure (2016)
Cost-effectiveness analysis: sleeping with an enemy or a friend?
Authors: S C Gulati, J D Bitran
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.9.2152 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7666072 Cost-effectiveness analysis: sleeping with an enemy or a friend? S C GulatixS C GulatiSearch for articles by this author , J D BitranxJ D BitranSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.9.2152 First Page PDF © 1995 by American Society of Clinical Oncology
Cost of Inpatient Care of Patients With Pemphigus in the United States
Authors: Adela R. Cardones, Russell P. Hall
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Cell- and Antibody-Mediated Immune Reactions of Patients to Cultured Cells of Breast Carcinoma&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Joseph G. Sinkovics, William J. Reeves, Jerry R. Cabiness
Journal: JNCI Journal of the National Cancer Institute (1972)

Tumor antigen-distinctive blocking serum globulins can inhibit the cytotoxic effect of lymphocytes “activated” against tumor antigens. A population of lymphocytes lost its cytotoxic effect upon contact with cultured human mammary carcinoma cells.
Diverse crowds using diverse methods improves the scientific dialectic
Authors: Matt Motyl, Ravi Iyer
Journal: Behavioral and Brain Sciences (2015)

Abstract In science, diversity is vital to the development of new knowledge. We agree with Duarte et al. that we need more political diversity in social psychology, but contend that we need more religious diversity and methodological diversity as well. If some diversity is good, more is better (especially in science).
Combined Neoplastic Effects of Vaccinia Virus and 3-Methylcholanthrene. III. Susceptibility and Resistance in Transplanted Mouse Skin2
Authors: Maria L. Duran-Reynals, Martin Zisblatt, Frank Lilly
Journal: JNCI Journal of the National Cancer Institute (1973)

In cortisone-pretreated mice, susceptibility to the acute, local effects of vaccinia virus was correlated with susceptibility to the neoplastic effects of 3-methylcholanthrene (MCA) painting. To determine the relative importance of local versus systemic factors in these responses, susceptibility and resistance to both agents were investigated in transplanted skin. (BALB/c × AKR)F1 hybrids, susceptible to both agents, received skin grafts from either resistant AKR or even more highly susceptible BALB/c parental mice. Control groups included isografted AKR, BALB/c, and (BALB/c × AKR)F11 mice. After the grafts had healed, the mice first received cortisone and then vaccinia virus inoculated intradermally into the graft. MCA was then painted over both the grafted and adjacent host skin. Since vaccinia virus infection spread into the host skin, the acute effects of the virus and the neoplastic effects of the carcinogen could be observed in both graft and host skin. Isografting did not modify the responses of the skin. In F1 mice bearing AKR skin, the graft remained resistant to both agents and the surrounding host skin remained susceptible to both; in hybrids bearing BALB/c skin, the grafts and the host skin were susceptible to both agents. These findings indicate that susceptibility or resistance to both vaccinia virus and MCA painting is determined by local rather than systemic factors, presumably at the level of the target cell.
BMA is encouraged by Hunt’s reassurances on junior doctors’ contract but seeks clarification
Authors: Abi Rimmer
Journal: BMJ (2015)

The BMA says that it is “encouraged” by a letter from the health secretary, Jeremy Hunt, responding to concerns about the proposed new contract for junior doctors in England, but it added that it wants further clarification.

In the letter to Johann Malawana, chair of the BMA’s Junior Doctors Committee, Hunt said that the new contract would not cut junior doctors’ pay or increase their working hours.

Malawana said, “It is encouraging that the health secretary has finally recognised the vital role that junior doctors play as tomorrow’s leaders across the NHS. However, questions still remain, and we are urgently seeking clarification on the points raised in the letter.”

In the letter Hunt discussed junior doctors’ concerns about the proposed new contract, including changes to plain time working that would include Saturdays.1 He said that, for junior doctors, the …